It has recently been investigated the role of CaSR in lethal prostate cancers, where higher CaSR tumour expression was associated with an approximately 2-fold higher risk for lethal progression, independently of Gleason grade and pathological stage [46]. The gene discussed is CASR; the disease is neoplasm.